Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study

Table 2 Factors associated with recent HCV testing (n = 550); univariable and multivariable logistic regression analyses

	Univariable logistic regression			Multivariable logistic regression
	OR	CI	p	aOR	CI	p
Questionnaire
Online	1.00			1.00
Face-to-face	1.84	[1.20,2.83]	0.005	1.65	[1.03,2.63]	0.037
Age	0.98	[0.96,1.00]	0.113	0.97	[0.95,1.00]	0.030
Gender
Men	1.00
Women	0.77	[0.48,1.25]	0.290
Employment
Unemployed	1.00			1.00
Employed	0.50	[0.33,0.78]	0.002	0.58	[0.37,0.92]	0.019
Unstable housing
No	1.00
Yes	1.60	[1.06,2.43]	0.027
Recent incarceration
No	1.00
Yes	1.84	[1.10,3.06]	0.019
Currently on OAT
No	1.00
Yes	0.96	[0.65,1.43]	0.845
Opioid injected most frequently
Buprenorphine	1.00
Heroin	0.82	[0.48,1.38]	0.448
Morphine	0.96	[0.56,1.63]	0.873
Methadone	1.87	[0.87,4.01]	0.109
Other^a	0.85	[0.50,1.44]	0.543
Other non-opioid substances injected
No	1.00
Yes	1.35	[0.93,1.94]	0.111
Time since first opioid injection (years)	0.97	[0.95,1.00]	0.090
Drug injection frequency during the previous month (days)	1.00	[0.98,1.02]	0.764
Sharing injection equipment
No	1.00
Yes	0.88	[0.54,1.43]	0.601
Disclosure of injection practices^b
Yes	1.00			1.00
No	0.23	[0.09,0.59]	0.002	0.31	[0.12,0.82]	0.018

CI confidence interval, HCV hepatitis C virus, OR odds ratio, OAT opioid agonist therapy
^aOxycodone, codeine, others and missing
^bAddiction specialist, other specialist physician, nurse, general practitioner, pharmacist, harm reduction services worker, family, friends, internet forum

ISSN: 1477-7517